APNAR Pharma Acquires Aurex Laboratories
February 3, 2022
APNAR Pharma LP, a privately owned pharmaceutical company based in Chino, California, has acquired East Windsor, New Jersey–based Aurex Laboratories. The deal adds US FDA–approved finished dosage manufacturing capabilities to APNAR’s platform, expanding its U.S. footprint, pipeline capacity and contract manufacturing capabilities to support APNAR’s ANDAs and third‑party partners.
- Buyers
- APNAR Pharma LP
- Targets
- Aurex Laboratories
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Pfizer's Hospital Business Acquires Arixa Pharmaceuticals
October 22, 2020
Pharmaceuticals
Pfizer’s Hospital Business acquired Arixa Pharmaceuticals to advance development of Arixa’s lead oral prodrug ARX-1796, a potential oral beta-lactamase inhibitor + antibiotic combination. Financial terms were not disclosed; Arixa was a virtual, asset-light company based in Palo Alto and was advised by Four Oaks Partners on the transaction.
-
Ampersand Capital Partners Majority Recapitalizes Phosphorex
August 25, 2022
Healthcare Services
Ampersand Capital Partners completed a majority recapitalization of Phosphorex to provide growth capital enabling the company to build out a 30,000 sq. ft. facility and establish cGMP manufacturing capabilities for lipid nanoparticles, microspheres and other drug-delivery platforms. The investment positions Phosphorex to expand from development and analytical services into end-to-end CDMO manufacturing to better serve pharmaceutical and biotechnology clients.
-
Adragos Pharma Acquires Baccinex
February 6, 2025
Pharmaceuticals
Adragos Pharma, a Munich-headquartered CDMO, has acquired Baccinex, a Swiss sterile fill-finish specialist based in Courroux, Jura. The acquisition adds a US FDA- and EU-GMP-certified 6,200 m² facility and over 110 sterile fill-finish experts to Adragos' global manufacturing network, enhancing its clinical and commercial sterile manufacturing capabilities.
-
Pfizer Acquires Amplyx Pharmaceuticals
April 28, 2021
Biotechnology
Pfizer Inc. acquired Amplyx Pharmaceuticals, a privately held clinical-stage biotechnology company developing the antifungal candidate fosmanogepix (APX001). The deal expands Pfizer's anti-infectives pipeline and secures Amplyx's lead and early-stage assets to advance development of novel antifungal and antiviral therapies.
-
Ampersand Capital Partners Acquires Purna Pharmaceuticals
February 12, 2026
Pharmaceuticals
Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider of liquid and semi-solid pharmaceutical dosage forms. The investment positions Purna to collaborate with Ampersand portfolio company MedPharm to create a trans‑Atlantic topical and transdermal development and manufacturing offering; Creafund, Purna's prior investor, supported the company for more than a decade and was referenced in the transaction announcement.
-
AmerisourceBergen Acquires PharmaLex from AUCTUS in €1.28bn Transaction
December 31, 2022
Healthcare Services
AmerisourceBergen Corporation acquired a majority stake in PharmaLex from funds advised by AUCTUS Capital Partners AG in a transaction that closed at year-end 2022 for approximately EUR 1.28 billion. PharmaLex, a Germany-headquartered provider of regulatory, clinical development and pharmacovigilance services to the life sciences industry, was grown under AUCTUS through a buy-and-build program of 38 add-ons and will expand AmerisourceBergen's global pharmaceutical solutions.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.